Shares of Amedisys Inc (NASDAQ:AMED) traded down 5.8% on Monday . The company traded as low as $51.16 and last traded at $52.08. 728,379 shares traded hands during trading, an increase of 117% from the average session volume of 335,921 shares. The stock had previously closed at $55.31.

A number of analysts have weighed in on the company. Robert W. Baird reiterated a “hold” rating and set a $50.00 price target on shares of Amedisys in a report on Wednesday, October 4th. Mizuho reaffirmed a “buy” rating and issued a $65.00 price target (up previously from $55.00) on shares of Amedisys in a research report on Wednesday, November 8th. Benchmark reaffirmed a “hold” rating on shares of Amedisys in a research report on Thursday, November 9th. Craig Hallum reaffirmed a “buy” rating and issued a $68.00 price target (up previously from $55.00) on shares of Amedisys in a research report on Thursday, November 9th. Finally, Oppenheimer reaffirmed a “buy” rating and issued a $60.00 price target on shares of Amedisys in a research report on Friday, September 15th. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Amedisys currently has a consensus rating of “Buy” and an average price target of $61.00.

The company has a debt-to-equity ratio of 0.16, a current ratio of 1.33 and a quick ratio of 1.33. The company has a market cap of $1,767.42, a PE ratio of 24.92, a P/E/G ratio of 1.26 and a beta of 0.70.

Amedisys (NASDAQ:AMED) last posted its earnings results on Tuesday, November 7th. The health services provider reported $0.56 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.54 by $0.02. Amedisys had a net margin of 2.88% and a return on equity of 14.68%. The firm had revenue of $380.20 million for the quarter, compared to analysts’ expectations of $384.59 million. During the same quarter last year, the firm earned $0.36 EPS. The company’s quarterly revenue was up 5.1% compared to the same quarter last year. sell-side analysts expect that Amedisys Inc will post 2.23 EPS for the current year.

Several large investors have recently bought and sold shares of AMED. Riverhead Capital Management LLC grew its stake in Amedisys by 75.5% in the 2nd quarter. Riverhead Capital Management LLC now owns 1,931 shares of the health services provider’s stock valued at $121,000 after buying an additional 831 shares in the last quarter. Federated Investors Inc. PA grew its position in Amedisys by 2.3% in the second quarter. Federated Investors Inc. PA now owns 1,929 shares of the health services provider’s stock worth $122,000 after acquiring an additional 44 shares in the last quarter. Quantitative Systematic Strategies LLC purchased a new position in Amedisys in the third quarter worth $205,000. SG Americas Securities LLC grew its position in Amedisys by 48.7% in the second quarter. SG Americas Securities LLC now owns 3,743 shares of the health services provider’s stock worth $235,000 after acquiring an additional 1,226 shares in the last quarter. Finally, Amalgamated Bank purchased a new position in Amedisys in the second quarter worth $246,000. 94.44% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Amedisys (AMED) Shares Down 5.8%” was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright legislation. The original version of this story can be accessed at https://www.watchlistnews.com/amedisys-amed-shares-down-5-8/1774636.html.

About Amedisys

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.